These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100 [TBL] [Abstract][Full Text] [Related]
23. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS). Choquet S; Marchal C; Deygas F; Deslandes M; Macher N; de Pouvourville G; Levy V Ann Hematol; 2024 Aug; 103(8):2969-2981. PubMed ID: 38965145 [TBL] [Abstract][Full Text] [Related]
24. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Lama TG; Kyung D; O'Brien S Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127 [TBL] [Abstract][Full Text] [Related]
25. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib. Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983 [TBL] [Abstract][Full Text] [Related]
26. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
27. Dabigatran in ibrutinib-treated patients with atrial fibrillation and chronic lymphocytic leukemia: experience of three cases. Santoro RC; Falbo M; Levato L; Iannaccaro P; Prejanò S Blood Coagul Fibrinolysis; 2021 Mar; 32(2):159-161. PubMed ID: 33273263 [TBL] [Abstract][Full Text] [Related]
34. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. McDermott J; Jimeno A Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646 [TBL] [Abstract][Full Text] [Related]
35. Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Gallais F; Ysebaert L; Despas F; De Barros S; Obéric L; Allal B; Chatelut E; White-Koning M Clin Pharmacol Ther; 2021 Jul; 110(1):220-228. PubMed ID: 33539551 [TBL] [Abstract][Full Text] [Related]
36. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Brown JR Leuk Lymphoma; 2014 Feb; 55(2):263-9. PubMed ID: 23656200 [TBL] [Abstract][Full Text] [Related]
38. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature. Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682 [TBL] [Abstract][Full Text] [Related]
39. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. O'Brien S; Furman RR; Coutre SE; Sharman JP; Burger JA; Blum KA; Grant B; Richards DA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Izumi R; Hamdy A; Chang BY; Graef T; Clow F; Buggy JJ; James DF; Byrd JC Lancet Oncol; 2014 Jan; 15(1):48-58. PubMed ID: 24332241 [TBL] [Abstract][Full Text] [Related]
40. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]